[HTML][HTML] Survival benefit and impact of adjuvant chemotherapy following systemic neoadjuvant chemotherapy in patients with resected pancreas ductal …
Background: Patients with pancreatic ductal adenocarcinoma (PDAC) are increasingly
receiving systemic neoadjuvant chemotherapy (NAC), particularly those with borderline …
receiving systemic neoadjuvant chemotherapy (NAC), particularly those with borderline …
Survival benefit and impact of adjuvant chemotherapy following systemic neoadjuvant chemotherapy in patients with resected pancreas ductal adenocarcinoma: A …
N Pu, W Wu, S Liu, Y Xie, H Yin, Q Chen, T He… - International Journal of … - journals.lww.com
Background: Patients with pancreatic ductal adenocarcinoma (PDAC) are increasingly
receiving systemic neoadjuvant chemotherapy (NAC), particularly those with borderline …
receiving systemic neoadjuvant chemotherapy (NAC), particularly those with borderline …
Survival benefit and impact of adjuvant chemotherapy following systemic neoadjuvant chemotherapy in patients with resected pancreas ductal adenocarcinoma: a …
N Pu, W Wu, S Liu, Y Xie, H Yin… - … Journal of Surgery, 2023 - pure.johnshopkins.edu
BACKGROUND: Patients with pancreatic ductal adenocarcinoma (PDAC) are increasingly
receiving systemic neoadjuvant chemotherapy (NAC), particularly those with borderline …
receiving systemic neoadjuvant chemotherapy (NAC), particularly those with borderline …
Survival benefit and impact of adjuvant chemotherapy following systemic neoadjuvant chemotherapy in patients with resected pancreas ductal adenocarcinoma: a …
N Pu, W Wu, S Liu, Y Xie, H Yin, Q Chen… - … Journal of Surgery …, 2023 - europepmc.org
Background Patients with pancreatic ductal adenocarcinoma (PDAC) are increasingly
receiving systemic neoadjuvant chemotherapy (NAC), particularly those with borderline …
receiving systemic neoadjuvant chemotherapy (NAC), particularly those with borderline …
[HTML][HTML] Survival benefit and impact of adjuvant chemotherapy following systemic neoadjuvant chemotherapy in patients with resected pancreas ductal …
N Pu, W Wu, S Liu, Y Xie, H Yin, Q Chen… - … Journal of Surgery …, 2023 - ncbi.nlm.nih.gov
Background: Patients with pancreatic ductal adenocarcinoma (PDAC) are increasingly
receiving systemic neoadjuvant chemotherapy (NAC), particularly those with borderline …
receiving systemic neoadjuvant chemotherapy (NAC), particularly those with borderline …
Survival benefit and impact of adjuvant chemotherapy following systemic neoadjuvant chemotherapy in patients with resected pancreas ductal adenocarcinoma: a …
N Pu, W Wu, S Liu, Y Xie, H Yin… - … journal of surgery …, 2023 - pubmed.ncbi.nlm.nih.gov
Background Patients with pancreatic ductal adenocarcinoma (PDAC) are increasingly
receiving systemic neoadjuvant chemotherapy (NAC), particularly those with borderline …
receiving systemic neoadjuvant chemotherapy (NAC), particularly those with borderline …
Survival benefit and impact of adjuvant chemotherapy following systemic neoadjuvant chemotherapy in patients with resected pancreas ductal adenocarcinoma: A …
N Pu, W Wu, S Liu, Y Xie, H Yin, Q Chen… - … Journal of Surgery …, 2023 - europepmc.org
Background Patients with pancreatic ductal adenocarcinoma (PDAC) are increasingly
receiving systemic neoadjuvant chemotherapy (NAC), particularly those with borderline …
receiving systemic neoadjuvant chemotherapy (NAC), particularly those with borderline …